• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results

    2/11/25 4:02:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GILD alert in real time by email

    Product Sales Excluding Veklury Increased 8% Year-Over-Year to $26.8 billion for Full Year 2024

    Biktarvy Sales Increased 13% Year-Over-Year to $13.4 billion for Full Year 2024

    Oncology Sales Increased 12% Year-Over-Year to $3.3 billion for Full Year 2024

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results of operations for the fourth quarter and full year 2024.

    "Gilead delivered another exceptionally strong full year and fourth quarter, with growth in our base business product sales of 8% for 2024 and 13% year-over-year for the fourth quarter," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "From this foundation of commercial strength, we are planning for the potential launch of lenacapavir for HIV PrEP in Summer 2025, with its unique opportunity to extend the reach of HIV prevention. This potential in HIV, along with our strong and diverse portfolio, and improved operational efficiencies, positions Gilead to deliver increasing patient impact and compelling shareholder returns in the years ahead."

    Fourth Quarter 2024 Financial Results

    • Total fourth quarter 2024 revenue increased 6% to $7.6 billion compared to the same period in 2023, primarily due to higher sales in HIV, as well as in Oncology and Liver Disease, partially offset by lower sales of Veklury® (remdesivir).
    • Diluted Earnings Per Share ("EPS") increased to $1.42 in the fourth quarter 2024 compared to $1.14 in the same period in 2023, primarily driven by lower costs of goods sold, higher product sales and lower acquired in-process research and development ("IPR&D") expenses, partially offset by higher operating expenses as well as unrealized losses on equity investments in 2024 compared to gains in 2023.
    • Non-GAAP diluted EPS increased to $1.90 in the fourth quarter 2024 compared to $1.72 in the same period in 2023. The increase was primarily driven by higher product sales and lower acquired IPR&D expenses, partially offset by higher operating expenses.
    • As of December 31, 2024, Gilead had $10.0 billion of cash, cash equivalents and marketable debt securities compared to $8.4 billion as of December 31, 2023.
    • During the fourth quarter 2024, Gilead generated $3.0 billion in operating cash flow.
    • During the fourth quarter 2024, Gilead issued senior unsecured notes in an aggregate principal amount of $3.5 billion, paid cash dividends of $973 million and utilized $350 million to repurchase common stock.

    Fourth Quarter 2024 Product Sales

    Total fourth quarter 2024 product sales increased 7% to $7.5 billion compared to the same period in 2023. Total product sales excluding Veklury increased 13% to $7.2 billion compared to the same period in 2023, primarily due to higher sales in HIV, as well as in Oncology and Liver Disease.

    HIV product sales increased 16% to $5.5 billion in the fourth quarter 2024 compared to the same period in 2023, primarily driven by higher demand, higher average realized price and favorable inventory dynamics.

    • Biktarvy® (bictegravir 50mg/emtricitabine ("FTC") 200mg/tenofovir alafenamide ("TAF") 25mg) sales increased 21% to $3.8 billion in the fourth quarter 2024 compared to the same period in 2023, primarily driven by higher demand, favorable inventory dynamics and higher average realized price.
    • Descovy® (FTC 200mg/TAF 25mg) sales increased 21% to $616 million in the fourth quarter 2024 compared to the same period in 2023, primarily driven by higher demand, higher average realized price and favorable inventory dynamics.

    The Liver Disease portfolio sales increased 4% to $719 million in the fourth quarter 2024 compared to the same period in 2023. This was primarily driven by the launch of Livdelzi® (seladelpar) in primary biliary cholangitis ("PBC"), and increased demand in products for chronic hepatitis B virus ("HBV") and chronic hepatitis delta virus ("HDV"), partially offset by lower demand and average realized price in products for chronic hepatitis C virus ("HCV").

    Veklury sales decreased 53% to $337 million in the fourth quarter 2024 compared to the same period in 2023, primarily driven by lower rates of COVID-19 related hospitalizations, particularly in the United States.

    Cell Therapy product sales increased 5% to $488 million in the fourth quarter 2024 compared to the same period in 2023.

    • Yescarta® (axicabtagene ciloleucel) sales increased 6% to $390 million in the fourth quarter 2024 compared to the same period in 2023, primarily driven by higher average realized price and increased demand outside of the United States, partially offset by lower demand in the United States.
    • Tecartus® (brexucabtagene autoleucel) sales of $98 million in the fourth quarter 2024 were flat compared to the same period in 2023, reflecting increased demand outside of the United States, offset by lower demand in the United States.

    Trodelvy® (sacituzumab govitecan-hziy) sales increased 19% to $355 million in the fourth quarter 2024 compared to the same period in 2023, primarily driven by increased demand in all regions, as well as higher average realized price.

    Fourth Quarter 2024 Product Gross Margin, Operating Expenses and Tax

    • Product gross margin was 79.0% in the fourth quarter 2024 compared to 70.4% in the same period in 2023, primarily driven by prior year restructuring expenses related to changes in our manufacturing strategy. Non-GAAP product gross margin was 86.7% in the fourth quarter 2024 compared to 86.1% in the same period in 2023.
    • Research and development ("R&D") expenses were $1.6 billion in the fourth quarter 2024 compared to $1.4 billion in the same period in 2023, primarily due to incremental investments and clinical activities across our portfolio and the impact of a prior year valuation adjustment to the MYR-related contingent consideration that did not repeat. Non-GAAP R&D expenses were $1.6 billion in the fourth quarter 2024 compared to $1.5 billion in the same period in 2023, primarily due to incremental investments and clinical activities across our portfolio.
    • Acquired IPR&D expenses were $(11) million in the fourth quarter 2024, reflecting expenses related to the Terray Therapeutics, Inc. ("Terray") and Tubulis GmbH ("Tubulis") collaborations, offset by a favorable adjustment related to the CymaBay Therapeutics, Inc. ("CymaBay") acquisition.
    • Selling, general and administrative ("SG&A") and non-GAAP SG&A expenses were $1.9 billion in the fourth quarter 2024 compared to $1.6 billion in the same period in 2023, primarily driven by a litigation accrual and higher sales and marketing spending, including launch preparation activities for lenacapavir for the investigational use of HIV pre-exposure prophylaxis ("PrEP") as well as for Livdelzi.
    • The effective tax rate ("ETR") was 17.8% in the fourth quarter 2024 compared to 14.3% in the same period in 2023, primarily due to prior year settlements with tax authorities and non-taxable unrealized gains and losses on equity investments. Non-GAAP ETR was 19.2% in the fourth quarter 2024 compared to 17.1% in the same period in 2023, primarily due to prior year settlements with tax authorities.

    Full Year 2024 Financial Results

    • Total full year 2024 revenue increased 6% to $28.8 billion compared to 2023, primarily due to higher sales in HIV, Oncology and Liver Disease, partially offset by lower sales of Veklury.
    • Diluted EPS decreased to $0.38 in the full year 2024 compared to $4.50 in 2023. The decrease was primarily driven by a pre-tax IPR&D impairment charge of $4.2 billion, or $2.49 per share net of tax impact, related to assets acquired by Gilead from Immunomedics, Inc. ("Immunomedics") in 2020, and acquired IPR&D charges of $3.9 billion, or $3.14 per share, in the first quarter 2024 related to the acquisition of CymaBay, partially offset by higher product sales.
    • Non-GAAP diluted EPS decreased to $4.62 in the full year 2024 compared to $6.72 in 2023. This was primarily driven by higher acquired IPR&D expenses related to the CymaBay acquisition and higher income tax expense, partially offset by higher product sales.

    Full Year 2024 Product Sales

    Total full year 2024 product sales increased 6% to $28.6 billion compared to 2023. Total product sales excluding Veklury increased 8% to $26.8 billion in the full year 2024 compared to 2023, primarily driven by higher sales in HIV, Oncology and Liver Disease.

    HIV product sales increased 8% to $19.6 billion in the full year 2024 compared to 2023, primarily driven by higher demand, as well as the impact of higher average realized price.

    • Biktarvy sales increased 13% to $13.4 billion in the full year 2024 compared to 2023, primarily driven by higher demand.
    • Descovy sales increased 6% to $2.1 billion in the full year 2024 compared to 2023, primarily driven by higher demand, partially offset by lower average realized price.

    The Liver Disease portfolio sales increased 9% to $3.0 billion in the full year 2024 compared to 2023. The increase was primarily due to higher demand across all liver diseases.

    Veklury sales decreased 18% to $1.8 billion in the full year 2024 compared to 2023, primarily driven by lower rates of COVID-19 related hospitalizations.

    Cell Therapy product sales increased 6% to $2.0 billion in the full year 2024 compared to 2023.

    • Yescarta sales increased 5% to $1.6 billion in the full year 2024 compared to 2023, primarily driven by increased demand outside of the United States and higher average realized price, partially offset by lower demand in the United States.
    • Tecartus sales increased 9% to $403 million in the full year 2024 compared to 2023, primarily driven by increased demand outside of the United States, partially offset by lower demand in the United States.

    Trodelvy sales increased 24% to $1.3 billion in the full year 2024 compared to 2023, primarily driven by increased demand in all regions.

    Full Year 2024 Product Gross Margin, Operating Expenses and Tax

    • Product gross margin was 78.2% in the full year 2024 compared to 75.9% in 2023, primarily driven by prior year restructuring expenses related to changes in our manufacturing strategy. Non-GAAP product gross margin was 86.2% in the full year 2024 compared to 86.3% in 2023.
    • R&D expenses were $5.9 billion in the full year 2024 compared to $5.7 billion in 2023, primarily driven by restructuring costs and integration expenses related to the CymaBay acquisition. Non-GAAP R&D expenses of $5.7 billion in the full year 2024 were flat compared to 2023.
    • Acquired IPR&D expenses were $4.7 billion in the full year 2024 compared to $1.2 billion in 2023, primarily reflecting the acquisition of CymaBay.
    • SG&A expenses of $6.1 billion in the full year 2024 were flat compared to 2023, reflecting higher sales and marketing spending, including launch preparation activities for lenacapavir for the investigational use of HIV PrEP as well as for Livdelzi, integration costs related to the acquisition of CymaBay, and restructuring expenses, offset by lower expenses related to legal matters. Non-GAAP SG&A expenses were $5.9 billion in the full year 2024 compared to $6.1 billion in 2023, primarily driven by lower expenses related to legal matters, partially offset by higher sales and marketing spending, including launch preparation activities for lenacapavir for the investigational use of HIV PrEP as well as for Livdelzi.
    • The ETR was 30.5% in the full year 2024 compared to 18.2% in 2023, primarily driven by the non-deductible acquired IPR&D charge for CymaBay and prior year decrease in tax reserves that did not repeat, partially offset by the tax impact of a legal entity restructuring and Immunomedics IPR&D impairment expense, as well as current year settlements with tax authorities and remeasurement of certain deferred tax liabilities. Non-GAAP ETR was 25.9% in the full year 2024 compared to 15.2% in 2023, primarily due to the non-deductible acquired IPR&D charge for CymaBay and a prior year decrease in tax reserves that did not repeat, partially offset by current year settlements with tax authorities.

    Guidance and Outlook

    For the full-year 2025, Gilead expects:

    (in millions, except per share amounts)

     

    February 11, 2025 Guidance

     

    Low End

     

    High End

    Product sales

     

    $

    28,200

     

    $

    28,600

    Product sales excluding Veklury

     

    $

    26,800

     

    $

    27,200

    Veklury

     

    $

    1,400

     

    $

    1,400

    Diluted EPS

     

    $

    5.95

     

    $

    6.35

    Non-GAAP diluted EPS

     

    $

    7.70

     

    $

    8.10

    Additional information and a reconciliation between GAAP and non-GAAP financial information for the 2025 guidance is provided in the accompanying tables. The financial guidance is subject to a number of risks and uncertainties. See the Forward-Looking Statements section below.

    Key Updates Since Our Last Quarterly Release

    Virology

    • Presented new HIV data at the International Congress on Drug Therapy in HIV Infection ("HIV Glasgow 2024"). This included full results from the Phase 3 PURPOSE 2 trial evaluating investigational twice-yearly lenacapavir for HIV prevention among cisgender men and gender-diverse people, with data published in the New England Journal of Medicine.
    • Additionally at HIV Glasgow 2024, presented new HIV treatment research data from Biktarvy, as well as for investigational regimens with once-daily, once-weekly and twice-yearly dosing frequencies.
    • Completed the New Drug Application submissions to U.S. Food and Drug Administration ("FDA"), as well as a marketing authorization application and an EU-Medicines for All application to the European Medicines Agency ("EMA"), for twice-yearly lenacapavir for HIV prevention.
    • Lenacapavir named by Science Magazine as its 2024 "Breakthrough of the Year," based in part on the PURPOSE 1 and PURPOSE 2 trial results.

    Oncology

    • Our partner, Arcellx, Inc. ("Arcellx"), presented new data evaluating investigational anitocabtagene autoleucel ("anito-cel") in relapsed or refractory ("R/R") multiple myeloma at the American Society of Hematology 2024 Annual Meeting ("ASH 2024"). This included preliminary data from the registrational Phase 2 iMMagine-1 trial, as well as updated Phase 1 data.
    • Presented new data at ASH 2024 including long-term follow-up of Yescarta in R/R non-Hodgkin's lymphoma and Tecartus in R/R mantle cell lymphoma, as well as real world data for Yescarta in R/R large B-cell lymphoma and Tecartus in B-cell precursor adult acute lymphoblastic leukemia.
    • Granted Breakthrough Therapy Designation by FDA to Trodelvy for the treatment of adult patients with extensive-stage small cell lung cancer ("ES-SCLC") whose disease has progressed on or after platinum-based chemotherapy. The use of Trodelvy in ES-SCLC is investigational.
    • Entered into a single-asset focused collaboration, license, and option agreement with Tubulis to develop an antibody-drug conjugate candidate for a solid tumor target using Tubulis' Tubutecan and Alco5 platforms.

    Inflammation

    • Received a positive opinion from the EMA's Committee for Medicinal Products for Human Use recommending seladelpar for the treatment of PBC in combination with ursodeoxycholic acid ("UDCA") in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.
    • Received marketing authorization from the Medicines and Healthcare products Regulatory Agency in the UK for seladelpar for treatment of PBC, including pruritus, in adults in combination with UDCA who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.
    • Presented new data evaluating seladelpar in PBC at the American Association for the Study of Liver Diseases' The Liver Meeting. This included longer-term follow-up data from the ASSURE trial, as well as additional analyses from the RESPONSE trial.
    • Announced a strategic partnership to develop and commercialize the pre-clinical oral STAT6 program of LEO Pharma A/S ("LEO Pharma") for the potential treatment of inflammatory diseases.

    Corporate

    • Appointed Dietmar Berger, MD, PhD, as Chief Medical Officer effective January 2025.
    • Entered into a strategic research collaboration with Terray to discover and develop novel, small molecule therapies across multiple targets using Terray's artificial intelligence tNOVA platform.
    • Reached a final settlement agreement with the U.S. Department of Justice and the U.S. Department of Health and Human Services on patents that the government alleged covered Truvada® (FTC 200mg/tenofovir disoproxil fumarate ("TDF") 300mg) and Descovy for HIV PrEP.
    • Issued $3.5 billion aggregate principal amount of senior unsecured notes in a registered offering.
    • The Board declared a quarterly dividend of $0.79 per share of common stock for the first quarter of 2025. The dividend is payable on March 28, 2025, to stockholders of record at the close of business on March 14, 2025. Future dividends will be subject to Board approval.

    Certain amounts and percentages in this press release may not sum or recalculate due to rounding.

    Conference Call

    At 1:30 p.m. Pacific Time today, Gilead will host a conference call to discuss Gilead's results. A live webcast will be available on http://investors.gilead.com and will be archived on www.gilead.com for one year.

    Non-GAAP Financial Information

    The information presented in this document has been prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead's GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under GAAP. Non-GAAP financial information generally excludes acquisition-related expenses including amortization of acquired intangible assets and other items that are considered unusual or not representative of underlying trends of Gilead's business, fair value adjustments of equity securities and discrete and related tax charges or benefits associated with such exclusions as well as changes in tax-related laws and guidelines, transfers of intangible assets between certain legal entities, and legal entity restructurings. Although Gilead consistently excludes the amortization of acquired intangible assets from the non-GAAP financial information, management believes that it is important for investors to understand that such intangible assets were recorded as part of acquisitions and contribute to ongoing revenue generation. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the accompanying tables.

    About Gilead Sciences

    Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

    Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead's ability to achieve its full year 2025 financial guidance, including as a result of the uncertainty of the amount and timing of Veklury revenues; Gilead's ability to make progress on any of its long-term ambitions or priorities laid out in its corporate strategy; Gilead's ability to accelerate or sustain revenues for its virology, oncology and other programs; Gilead's ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements, including the arrangements with Arcellx, LEO Pharma, Terray and Tubulis; patent protection and estimated loss of exclusivity for our products and product candidates; Gilead's ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Biktarvy, Tecartus, Trodelvy, Yescarta, anito-cel, lenacapavir and seladelpar (such as the ASSURE, iMMagine-1, PURPOSE 1 and 2, and RESPONSE studies), and the risk that safety and efficacy data from clinical trials may not warrant further development of Gilead's product candidates or the product candidates of Gilead's strategic partners; Gilead's ability to submit new drug applications for new product candidates or expanded indications in the currently anticipated timelines, including for lenacapavir for HIV PrEP and seladelpar for PBC; Gilead's ability to receive or maintain regulatory approvals in a timely manner or at all, and the risk that any such approvals, if granted, may be subject to significant limitations on use and may be subject to withdrawal or other adverse actions by the applicable regulatory authority; Gilead's ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead's products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of Gilead's products over other therapies and may therefore be reluctant to prescribe the products, including Livdelzi; and other risks identified from time to time in Gilead's reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Further, results for the quarter ended December 31, 2024 are not necessarily indicative of operating results for any future periods. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

    The reader is cautioned that forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.

    Gilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD®, GILEAD SCIENCES®, KITETM, AMBISOME®, ATRIPLA®, BIKTARVY®, CAYSTON®, COMPLERA®, DESCOVY®, DESCOVY FOR PREP®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPCLUDEX®, HEPSERA®, JYSELECA®, LIVDELZI®, LETAIRIS®, ODEFSEY®, SOVALDI®, STRIBILD®, SUNLENCA® , TECARTUS®, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®, TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA® and ZYDELIG®.

    For more information on Gilead Sciences, Inc., please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

     
     
     

    GILEAD SCIENCES, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (unaudited)

     

     

     

    Three Months Ended

     

    Twelve Months Ended

     

     

    December 31,

     

    December 31,

    (in millions, except per share amounts)

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Revenues:

     

     

     

     

     

     

     

     

    Product sales

     

    $

    7,536

     

     

    $

    7,070

     

     

    $

    28,610

     

     

    $

    26,934

     

    Royalty, contract and other revenues

     

     

    33

     

     

     

    45

     

     

     

    144

     

     

     

    182

     

    Total revenues

     

     

    7,569

     

     

     

    7,115

     

     

     

    28,754

     

     

     

    27,116

     

    Costs and expenses:

     

     

     

     

     

     

     

     

    Cost of goods sold

     

     

    1,581

     

     

     

    2,090

     

     

     

    6,251

     

     

     

    6,498

     

    Research and development expenses

     

     

    1,641

     

     

     

    1,408

     

     

     

    5,907

     

     

     

    5,718

     

    Acquired in-process research and development expenses

     

     

    (11

    )

     

     

    347

     

     

     

    4,663

     

     

     

    1,155

     

    In-process research and development impairments

     

     

    —

     

     

     

    50

     

     

     

    4,180

     

     

     

    50

     

    Selling, general and administrative expenses

     

     

    1,906

     

     

     

    1,608

     

     

     

    6,091

     

     

     

    6,090

     

    Total costs and expenses

     

     

    5,118

     

     

     

    5,503

     

     

     

    27,092

     

     

     

    19,511

     

    Operating income

     

     

    2,451

     

     

     

    1,612

     

     

     

    1,662

     

     

     

    7,605

     

    Interest expense

     

     

    248

     

     

     

    252

     

     

     

    977

     

     

     

    944

     

    Other (income) expense, net

     

     

    35

     

     

     

    (293

    )

     

     

    (6

    )

     

     

    (198

    )

    Income before income taxes

     

     

    2,168

     

     

     

    1,653

     

     

     

    690

     

     

     

    6,859

     

    Income tax expense

     

     

    385

     

     

     

    236

     

     

     

    211

     

     

     

    1,247

     

    Net income

     

     

    1,783

     

     

     

    1,417

     

     

     

    480

     

     

     

    5,613

     

    Net loss attributable to noncontrolling interest

     

     

    —

     

     

     

    (12

    )

     

     

    —

     

     

     

    (52

    )

    Net income attributable to Gilead

     

    $

    1,783

     

     

    $

    1,429

     

     

    $

    480

     

     

    $

    5,665

     

    Basic earnings per share attributable to Gilead

     

    $

    1.43

     

     

    $

    1.15

     

     

    $

    0.38

     

     

    $

    4.54

     

    Shares used in basic earnings per share attributable to Gilead calculation

     

     

    1,248

     

     

     

    1,248

     

     

     

    1,247

     

     

     

    1,248

     

    Diluted earnings per share attributable to Gilead

     

    $

    1.42

     

     

    $

    1.14

     

     

    $

    0.38

     

     

    $

    4.50

     

    Shares used in diluted earnings per share attributable to Gilead calculation

     

     

    1,259

     

     

     

    1,256

     

     

     

    1,255

     

     

     

    1,258

     

     

     

     

     

     

     

     

     

     

    Supplemental Information:

     

     

     

     

     

     

     

     

    Cash dividends declared per share

     

    $

    0.77

     

     

    $

    0.75

     

     

    $

    3.08

     

     

    $

    3.00

     

    Product gross margin

     

     

    79.0

    %

     

     

    70.4

    %

     

     

    78.2

    %

     

     

    75.9

    %

    Research and development expenses as a % of revenues

     

     

    21.7

    %

     

     

    19.8

    %

     

     

    20.5

    %

     

     

    21.1

    %

    Selling, general and administrative expenses as a % of revenues

     

     

    25.2

    %

     

     

    22.6

    %

     

     

    21.2

    %

     

     

    22.5

    %

    Operating margin

     

     

    32.4

    %

     

     

    22.7

    %

     

     

    5.8

    %

     

     

    28.0

    %

    Effective tax rate

     

     

    17.8

    %

     

     

    14.3

    %

     

     

    30.5

    %

     

     

    18.2

    %

     
     
     

    GILEAD SCIENCES, INC.

    TOTAL REVENUE SUMMARY

    (unaudited)

     

     

     

     

    Three Months Ended

     

     

     

    Twelve Months Ended

     

     

     

     

    December 31,

     

     

     

    December 31,

     

     

    (in millions, except percentages)

     

    2024

     

    2023

     

    Change

     

    2024

     

    2023

     

    Change

    Product sales:

     

     

     

     

     

     

     

     

     

     

     

     

    HIV

     

    $

    5,452

     

    $

    4,693

     

    16%

     

    $

    19,612

     

    $

    18,175

     

    8%

    Liver Disease

     

     

    719

     

     

    691

     

    4%

     

     

    3,021

     

     

    2,784

     

    9%

    Oncology

     

     

    843

     

     

    765

     

    10%

     

     

    3,289

     

     

    2,932

     

    12%

    Other

     

     

    184

     

     

    201

     

    (8)%

     

     

    889

     

     

    859

     

    3%

    Total product sales excluding Veklury

     

     

    7,198

     

     

    6,350

     

    13%

     

     

    26,811

     

     

    24,750

     

    8%

    Veklury

     

     

    337

     

     

    720

     

    (53)%

     

     

    1,799

     

     

    2,184

     

    (18)%

    Total product sales

     

     

    7,536

     

     

    7,070

     

    7%

     

     

    28,610

     

     

    26,934

     

    6%

    Royalty, contract and other revenues

     

     

    33

     

     

    45

     

    (26)%

     

     

    144

     

     

    182

     

    (21)%

    Total revenues

     

    $

    7,569

     

    $

    7,115

     

    6%

     

    $

    28,754

     

    $

    27,116

     

    6%

     
     
     

    GILEAD SCIENCES, INC.

    NON-GAAP FINANCIAL INFORMATION(1)

    (unaudited)

     

     

     

     

    Three Months Ended

     

     

     

    Twelve Months Ended

     

     

     

     

    December 31,

     

     

     

    December 31,

     

     

    (in millions, except percentages)

     

     

    2024

     

     

     

    2023

     

     

    Change

     

     

    2024

     

     

     

    2023

     

     

    Change

    Non-GAAP:

     

     

     

     

     

     

     

     

     

     

     

     

    Cost of goods sold

     

    $

    1,002

     

     

    $

    980

     

     

    2%

     

    $

    3,936

     

     

    $

    3,697

     

     

    6%

    Research and development expenses

     

    $

    1,612

     

     

    $

    1,452

     

     

    11%

     

    $

    5,732

     

     

    $

    5,720

     

     

    —%

    Acquired IPR&D expenses(2)

     

    $

    (11

    )

     

    $

    347

     

     

    NM

     

    $

    4,663

     

     

    $

    1,155

     

     

    NM

    Selling, general and administrative expenses

     

    $

    1,852

     

     

    $

    1,597

     

     

    16%

     

    $

    5,903

     

     

    $

    6,060

     

     

    (3)%

    Other (income) expense, net

     

    $

    (91

    )

     

    $

    (104

    )

     

    (13)%

     

    $

    (279

    )

     

    $

    (365

    )

     

    (24)%

    Diluted EPS

     

    $

    1.90

     

     

    $

    1.72

     

     

    10%

     

    $

    4.62

     

     

    $

    6.72

     

     

    (31)%

    Shares used in non-GAAP diluted earnings per share attributable to Gilead calculation

     

     

    1,259

     

     

     

    1,256

     

     

    —%

     

     

    1,255

     

     

     

    1,258

     

     

    —%

     

     

     

     

     

     

     

     

     

     

     

     

     

    Product gross margin

     

     

    86.7

    %

     

     

    86.1

    %

     

    56 bps

     

     

    86.2

    %

     

     

    86.3

    %

     

    -3 bps

    Research and development expenses as a % of revenues

     

     

    21.3

    %

     

     

    20.4

    %

     

    89 bps

     

     

    19.9

    %

     

     

    21.1

    %

     

    -116 bps

    Selling, general and administrative expenses as a % of revenues

     

     

    24.5

    %

     

     

    22.4

    %

     

    203 bps

     

     

    20.5

    %

     

     

    22.3

    %

     

    -182 bps

    Operating margin

     

     

    41.1

    %

     

     

    38.5

    %

     

    265 bps

     

     

    29.6

    %

     

     

    38.7

    %

     

    -903 bps

    Effective tax rate

     

     

    19.2

    %

     

     

    17.1

    %

     

    210 bps

     

     

    25.9

    %

     

     

    15.2

    %

     

    1075 bps

    ________________________________

    NM - Not Meaningful

    (1)

    Refer to Non-GAAP Financial Information section above for further disclosures on non-GAAP financial measures. A reconciliation between GAAP and non-GAAP financial information is provided in the tables below.

    (2)

    Equal to GAAP financial information.

     
     
     

    GILEAD SCIENCES, INC.

    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

    (unaudited)

     

     

     

    Three Months Ended

     

    Twelve Months Ended

     

     

    December 31,

     

    December 31,

    (in millions, except percentages and per share amounts)

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Cost of goods sold reconciliation:

     

     

     

     

     

     

     

     

    GAAP cost of goods sold

     

    $

    1,581

     

     

    $

    2,090

     

     

    $

    6,251

     

     

    $

    6,498

     

    Acquisition-related – amortization(1)

     

     

    (579

    )

     

     

    (580

    )

     

     

    (2,316

    )

     

     

    (2,271

    )

    Restructuring

     

     

    —

     

     

     

    (479

    )

     

     

    —

     

     

     

    (479

    )

    Other(2)

     

     

    —

     

     

     

    (51

    )

     

     

    —

     

     

     

    (51

    )

    Non-GAAP cost of goods sold

     

    $

    1,002

     

     

    $

    980

     

     

    $

    3,936

     

     

    $

    3,697

     

     

     

     

     

     

     

     

     

     

    Product gross margin reconciliation:

     

     

     

     

     

     

     

     

    GAAP product gross margin

     

     

    79.0

    %

     

     

    70.4

    %

     

     

    78.2

    %

     

     

    75.9

    %

    Acquisition-related – amortization(1)

     

     

    7.7

    %

     

     

    8.2

    %

     

     

    8.1

    %

     

     

    8.4

    %

    Restructuring

     

     

    —

    %

     

     

    6.8

    %

     

     

    (—

    )%

     

     

    1.8

    %

    Other(2)

     

     

    —

    %

     

     

    0.7

    %

     

     

    —

    %

     

     

    0.2

    %

    Non-GAAP product gross margin

     

     

    86.7

    %

     

     

    86.1

    %

     

     

    86.2

    %

     

     

    86.3

    %

     

     

     

     

     

     

     

     

     

    Research and development expenses reconciliation:

     

     

     

     

     

     

     

     

    GAAP research and development expenses

     

    $

    1,641

     

     

    $

    1,408

     

     

    $

    5,907

     

     

    $

    5,718

     

    Acquisition-related – other costs(3)

     

     

    —

     

     

     

    59

     

     

     

    (78

    )

     

     

    22

     

    Restructuring

     

     

    (30

    )

     

     

    (15

    )

     

     

    (98

    )

     

     

    (20

    )

    Non-GAAP research and development expenses

     

    $

    1,612

     

     

    $

    1,452

     

     

    $

    5,732

     

     

    $

    5,720

     

     

     

     

     

     

     

     

     

     

    IPR&D impairment reconciliation:

     

     

     

     

     

     

     

     

    GAAP IPR&D impairment

     

    $

    —

     

     

    $

    50

     

     

    $

    4,180

     

     

    $

    50

     

    IPR&D impairment

     

     

    —

     

     

     

    (50

    )

     

     

    (4,180

    )

     

     

    (50

    )

    Non-GAAP IPR&D impairment

     

    $

    —

     

     

    $

    —

     

     

    $

    —

     

     

    $

    —

     

     

     

     

     

     

     

     

     

     

    Selling, general and administrative expenses reconciliation:

     

     

     

     

     

     

     

     

    GAAP selling, general and administrative expenses

     

    $

    1,906

     

     

    $

    1,608

     

     

    $

    6,091

     

     

    $

    6,090

     

    Acquisition-related – other costs(3)

     

     

    (8

    )

     

     

    —

     

     

     

    (97

    )

     

     

    (2

    )

    Restructuring

     

     

    (46

    )

     

     

    (11

    )

     

     

    (91

    )

     

     

    (28

    )

    Non-GAAP selling, general and administrative expenses

     

    $

    1,852

     

     

    $

    1,597

     

     

    $

    5,903

     

     

    $

    6,060

     

     

     

     

     

     

     

     

     

     

    Operating income reconciliation:

     

     

     

     

     

     

     

     

    GAAP operating income

     

    $

    2,451

     

     

    $

    1,612

     

     

    $

    1,662

     

     

    $

    7,605

     

    Acquisition-related – amortization(1)

     

     

    579

     

     

     

    580

     

     

     

    2,316

     

     

     

    2,271

     

    Acquisition-related – other costs(3)

     

     

    8

     

     

     

    (59

    )

     

     

    174

     

     

     

    (20

    )

    Restructuring

     

     

    76

     

     

     

    505

     

     

     

    188

     

     

     

    527

     

    IPR&D impairment

     

     

    —

     

     

     

    50

     

     

     

    4,180

     

     

     

    50

     

    Other(2)

     

     

    —

     

     

     

    51

     

     

     

    —

     

     

     

    51

     

    Non-GAAP operating income

     

    $

    3,114

     

     

    $

    2,739

     

     

    $

    8,520

     

     

    $

    10,484

     

     

     

     

     

     

     

     

     

     

    Operating margin reconciliation:

     

     

     

     

     

     

     

     

    GAAP operating margin

     

     

    32.4

    %

     

     

    22.7

    %

     

     

    5.8

    %

     

     

    28.0

    %

    Acquisition-related – amortization(1)

     

     

    7.6

    %

     

     

    8.1

    %

     

     

    8.1

    %

     

     

    8.4

    %

    Acquisition-related – other costs(3)

     

     

    0.1

    %

     

     

    (0.8

    )%

     

     

    0.6

    %

     

     

    (0.1

    )%

    Restructuring

     

     

    1.0

    %

     

     

    7.1

    %

     

     

    0.7

    %

     

     

    1.9

    %

    IPR&D impairment

     

     

    —

    %

     

     

    0.7

    %

     

     

    14.5

    %

     

     

    0.2

    %

    Other(2)

     

     

    —

    %

     

     

    0.7

    %

     

     

    —

    %

     

     

    0.2

    %

    Non-GAAP operating margin

     

     

    41.1

    %

     

     

    38.5

    %

     

     

    29.6

    %

     

     

    38.7

    %

     

     

     

     

     

     

     

     

     

    Other (income) expense, net reconciliation:

     

     

     

     

     

     

     

     

    GAAP other (income) expense, net

     

    $

    35

     

     

    $

    (293

    )

     

    $

    (6

    )

     

    $

    (198

    )

    (Loss) gain from equity securities, net

     

     

    (126

    )

     

     

    189

     

     

     

    (274

    )

     

     

    (167

    )

    Non-GAAP other (income) expense, net

     

    $

    (91

    )

     

    $

    (104

    )

     

    $

    (279

    )

     

    $

    (365

    )

     
     
     

    GILEAD SCIENCES, INC.

    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)

    (unaudited)

     

     

     

    Three Months Ended

     

    Twelve Months Ended

     

     

    December 31,

     

    December 31,

    (in millions, except percentages and per share amounts)

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Income before income taxes reconciliation:

     

     

     

     

     

     

     

     

    GAAP income before income taxes

     

    $

    2,168

     

     

    $

    1,653

     

     

    $

    690

     

     

    $

    6,859

     

    Acquisition-related – amortization(1)

     

     

    579

     

     

     

    580

     

     

     

    2,316

     

     

     

    2,271

     

    Acquisition-related – other costs(3)

     

     

    8

     

     

     

    (59

    )

     

     

    174

     

     

     

    (20

    )

    Restructuring

     

     

    76

     

     

     

    505

     

     

     

    188

     

     

     

    527

     

    IPR&D impairment

     

     

    —

     

     

     

    50

     

     

     

    4,180

     

     

     

    50

     

    Loss (gain) from equity securities, net

     

     

    126

     

     

     

    (189

    )

     

     

    274

     

     

     

    167

     

    Other(2)

     

     

    —

     

     

     

    51

     

     

     

    —

     

     

     

    51

     

    Non-GAAP income before income taxes

     

    $

    2,956

     

     

    $

    2,591

     

     

    $

    7,822

     

     

    $

    9,905

     

     

     

     

     

     

     

     

     

     

    Income tax expense reconciliation:

     

     

     

     

     

     

     

     

    GAAP income tax (benefit) expense

     

    $

    385

     

     

    $

    236

     

     

    $

    211

     

     

    $

    1,247

     

    Income tax effect of non-GAAP adjustments:

     

     

     

     

     

     

     

     

    Acquisition-related – amortization(1)

     

     

    121

     

     

     

    119

     

     

     

    484

     

     

     

    466

     

    Acquisition-related – other costs(3)

     

     

    2

     

     

     

    1

     

     

     

    41

     

     

     

    9

     

    Restructuring

     

     

    16

     

     

     

    90

     

     

     

    37

     

     

     

    95

     

    IPR&D impairment

     

     

    —

     

     

     

    15

     

     

     

    1,051

     

     

     

    15

     

    Loss (gain) from equity securities, net

     

     

    13

     

     

     

    (18

    )

     

     

    (39

    )

     

     

    (14

    )

    Discrete and related tax charges(4)

     

     

    29

     

     

     

    (12

    )

     

     

    243

     

     

     

    (326

    )

    Other(2)

     

     

    —

     

     

     

    11

     

     

     

    —

     

     

     

    11

     

    Non-GAAP income tax expense

     

    $

    566

     

     

    $

    442

     

     

    $

    2,028

     

     

    $

    1,503

     

     

     

     

     

     

     

     

     

     

    Effective tax rate reconciliation:

     

     

     

     

     

     

     

     

    GAAP effective tax rate

     

     

    17.8

    %

     

     

    14.3

    %

     

     

    30.5

    %

     

     

    18.2

    %

    Income tax effect of above non-GAAP adjustments and discrete and related tax adjustments(4)

     

     

    1.4

    %

     

     

    2.8

    %

     

     

    (4.6

    )%

     

     

    (3.0

    )%

    Non-GAAP effective tax rate

     

     

    19.2

    %

     

     

    17.1

    %

     

     

    25.9

    %

     

     

    15.2

    %

     

     

     

     

     

     

     

     

     

    Net income attributable to Gilead reconciliation:

     

     

     

     

     

     

     

     

    GAAP net income attributable to Gilead

     

    $

    1,783

     

     

    $

    1,429

     

     

    $

    480

     

     

    $

    5,665

     

    Acquisition-related – amortization(1)

     

     

    458

     

     

     

    460

     

     

     

    1,832

     

     

     

    1,805

     

    Acquisition-related – other costs(3)

     

     

    6

     

     

     

    (59

    )

     

     

    134

     

     

     

    (29

    )

    Restructuring

     

     

    59

     

     

     

    414

     

     

     

    151

     

     

     

    431

     

    IPR&D impairment

     

     

    —

     

     

     

    35

     

     

     

    3,129

     

     

     

    35

     

    Loss (gain) from equity securities, net

     

     

    113

     

     

     

    (171

    )

     

     

    313

     

     

     

    180

     

    Discrete and related tax charges(4)

     

     

    (29

    )

     

     

    12

     

     

     

    (243

    )

     

     

    326

     

    Other(2)

     

     

    —

     

     

     

    40

     

     

     

    —

     

     

     

    40

     

    Non-GAAP net income attributable to Gilead

     

    $

    2,390

     

     

    $

    2,161

     

     

    $

    5,795

     

     

    $

    8,454

     

     

     

     

     

     

     

     

     

     

    Diluted earnings per share reconciliation:

     

     

     

     

     

     

     

     

    GAAP diluted earnings per share

     

    $

    1.42

     

     

    $

    1.14

     

     

    $

    0.38

     

     

    $

    4.50

     

    Acquisition-related – amortization(1)

     

     

    0.36

     

     

     

    0.37

     

     

     

    1.46

     

     

     

    1.43

     

    Acquisition-related – other costs(3)

     

     

    —

     

     

     

    (0.05

    )

     

     

    0.11

     

     

     

    (0.02

    )

    Restructuring

     

     

    0.05

     

     

     

    0.33

     

     

     

    0.12

     

     

     

    0.34

     

    IPR&D impairment

     

     

    —

     

     

     

    0.03

     

     

     

    2.49

     

     

     

    0.03

     

    Loss (gain) from equity securities, net

     

     

    0.09

     

     

     

    (0.14

    )

     

     

    0.25

     

     

     

    0.14

     

    Discrete and related tax charges(4)

     

     

    (0.02

    )

     

     

    0.01

     

     

     

    (0.19

    )

     

     

    0.26

     

    Other(2)

     

     

    —

     

     

     

    0.03

     

     

     

    —

     

     

     

    0.03

     

    Non-GAAP diluted earnings per share

     

    $

    1.90

     

     

    $

    1.72

     

     

    $

    4.62

     

     

    $

    6.72

     

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended

     

    Twelve Months Ended

     

     

    December 31,

     

    December 31,

    (in millions, except percentages and per share amounts)

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Non-GAAP adjustment summary:

     

     

     

     

     

     

     

     

    Cost of goods sold adjustments

     

    $

    579

     

     

    $

    1,110

     

     

    $

    2,315

     

     

    $

    2,801

     

    Research and development expenses adjustments

     

     

    29

     

     

     

    (44

    )

     

     

    176

     

     

     

    (2

    )

    IPR&D impairment adjustments

     

     

    —

     

     

     

    50

     

     

     

    4,180

     

     

     

    50

     

    Selling, general and administrative expenses adjustments

     

     

    54

     

     

     

    11

     

     

     

    188

     

     

     

    30

     

    Total non-GAAP adjustments to costs and expenses

     

     

    663

     

     

     

    1,127

     

     

     

    6,858

     

     

     

    2,879

     

    Other (income) expense, net, adjustments

     

     

    126

     

     

     

    (189

    )

     

     

    274

     

     

     

    167

     

    Total non-GAAP adjustments before income taxes

     

     

    789

     

     

     

    938

     

     

     

    7,132

     

     

     

    3,046

     

    Income tax effect of non-GAAP adjustments above

     

     

    (152

    )

     

     

    (218

    )

     

     

    (1,574

    )

     

     

    (583

    )

    Discrete and related tax charges(4)

     

     

    (29

    )

     

     

    12

     

     

     

    (243

    )

     

     

    326

     

    Total non-GAAP adjustments to net income attributable to Gilead

     

    $

    607

     

     

    $

    732

     

     

    $

    5,315

     

     

    $

    2,789

     

    ________________________________

    (1)

    Relates to amortization of acquired intangibles.

    (2)

    Relates to a write-off of an intangible asset related to the restructuring of our collaboration with Galapagos NV during the fourth quarter of 2023.

    (3)

    Adjustments include integration expenses, contingent consideration fair value adjustments and other expenses associated with Gilead's recent acquisitions.

    (4)

    Represents discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and in-process research and development, transfers of intangible assets from a foreign subsidiary to Ireland and the United States, and legal entity restructurings.

     
     
     

    GILEAD SCIENCES, INC.

    RECONCILIATION OF GAAP TO NON-GAAP 2025 FULL YEAR GUIDANCE(1)

    (unaudited)

     

     

     

    (in millions, except percentages and per share amounts)

     

    Provided

    February 11, 2025

    Projected product gross margin GAAP to non-GAAP reconciliation:

     

     

    GAAP projected product gross margin

     

    77.0% - 78.0%

    Acquisition-related expenses

     

    ~ 8.0%

    Non-GAAP projected product gross margin

     

    85.0% - 86.0%

     

     

     

    Projected operating income GAAP to non-GAAP reconciliation:

     

     

    GAAP projected operating income

     

    $10,200 - $10,700

    Acquisition-related and restructuring expenses

     

    ~ 2,500

    Non-GAAP projected operating income

     

    $12,700 - $13,200

     

     

     

    Projected effective tax rate GAAP to non-GAAP reconciliation:

     

     

    GAAP projected effective tax rate

     

    ~ 20%

    Income tax effect of above non-GAAP adjustments, and discrete and related tax adjustments

     

    (~ 1%)

    Non-GAAP projected effective tax rate

     

    ~ 19%

     

     

     

    Projected diluted EPS GAAP to non-GAAP reconciliation:

     

     

    GAAP projected diluted EPS

     

    $5.95 - $6.35

    Acquisition-related and restructuring expenses, and discrete and related tax adjustments

     

    ~ 1.75

    Non-GAAP projected diluted EPS

     

    $7.70 - $8.10

    ________________________________

    (1)

    Our full-year guidance excludes the potential impact of any (i) acquisitions or business development transactions that have not been executed, (ii) future fair value adjustments of equity securities and (iii) discrete tax charges or benefits associated with changes in tax related laws and guidelines that have not been enacted, as Gilead is unable to project such amounts. The non-GAAP full-year guidance includes non-GAAP adjustments to actual current period results as well as adjustments for the known future impact associated with events that have already occurred, such as future amortization of our intangible assets and the future impact of discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and in-process research and development, transfers of intangible assets from a foreign subsidiary to Ireland and the United States, and legal entity restructurings.

     
     
     

    GILEAD SCIENCES, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (unaudited)

     

     

     

    December 31,

    (in millions)

     

    2024

     

    2023

    Assets

     

     

     

     

    Cash, cash equivalents and marketable debt securities

     

    $

    9,991

     

    $

    8,428

    Accounts receivable, net

     

     

    4,420

     

     

    4,660

    Inventories

     

     

    3,589

     

     

    3,366

    Property, plant and equipment, net

     

     

    5,414

     

     

    5,317

    Intangible assets, net

     

     

    19,948

     

     

    26,454

    Goodwill

     

     

    8,314

     

     

    8,314

    Other assets

     

     

    7,319

     

     

    5,586

    Total assets

     

    $

    58,995

     

    $

    62,125

    Liabilities and Stockholders' Equity

     

     

     

     

    Current liabilities

     

    $

    12,004

     

    $

    11,280

    Long-term liabilities

     

     

    27,744

     

     

    28,096

    Stockholders' equity(1)

     

     

    19,246

     

     

    22,749

    Total liabilities and stockholders' equity

     

    $

    58,995

     

    $

    62,125

    ________________________________

    (1)

    As of December 31, 2024 and 2023, there were 1,246 shares of common stock issued and outstanding.

     
     
     

    GILEAD SCIENCES, INC.

    SELECTED CASH FLOW INFORMATION

    (unaudited)

     

     

     

    Three Months Ended

     

    Twelve Months Ended

     

     

    December 31,

     

    December 31,

    (in millions)

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Net cash provided by operating activities

     

    $

    2,975

     

     

    $

    2,168

     

     

    $

    10,828

     

     

    $

    8,006

     

    Net cash used in investing activities

     

     

    (225

    )

     

     

    (726

    )

     

     

    (3,449

    )

     

     

    (2,265

    )

    Net cash used in financing activities

     

     

    2,260

     

     

     

    (1,100

    )

     

     

    (3,433

    )

     

     

    (5,125

    )

    Effect of exchange rate changes on cash and cash equivalents

     

     

    (55

    )

     

     

    37

     

     

     

    (40

    )

     

     

    57

     

    Net change in cash and cash equivalents

     

     

    4,954

     

     

     

    380

     

     

     

    3,906

     

     

     

    673

     

    Cash and cash equivalents at beginning of period

     

     

    5,037

     

     

     

    5,705

     

     

     

    6,085

     

     

     

    5,412

     

    Cash and cash equivalents at end of period

     

    $

    9,991

     

     

    $

    6,085

     

     

    $

    9,991

     

     

    $

    6,085

     

     

     

    Three Months Ended

     

    Twelve Months Ended

     

     

    December 31,

     

    December 31,

    (in millions)

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Net cash provided by operating activities

     

    $

    2,975

     

     

    $

    2,168

     

     

    $

    10,828

     

     

    $

    8,006

     

    Capital expenditures

     

     

    (147

    )

     

     

    (214

    )

     

     

    (523

    )

     

     

    (585

    )

    Free cash flow(1)

     

    $

    2,828

     

     

    $

    1,954

     

     

    $

    10,305

     

     

    $

    7,421

     

    ________________________________

    (1)

    Free cash flow is a non-GAAP liquidity measure. Please refer to our disclosures in the Non-GAAP Financial Information section above.

     
     
     

    GILEAD SCIENCES, INC.

    PRODUCT SALES SUMMARY

    (unaudited)

     

     

     

    Three Months Ended

     

    Twelve Months Ended

     

     

    December 31,

     

    December 31,

    (in millions)

     

    2024

     

    2023

     

    2024

     

    2023

    HIV

     

     

     

     

     

     

     

     

    Biktarvy – U.S.

     

    $

    3,129

     

    $

    2,588

     

    $

    10,855

     

    $

    9,692

    Biktarvy – Europe

     

     

    400

     

     

    333

     

     

    1,509

     

     

    1,253

    Biktarvy – Rest of World

     

     

    246

     

     

    188

     

     

    1,060

     

     

    905

     

     

     

    3,774

     

     

    3,109

     

     

    13,423

     

     

    11,850

     

     

     

     

     

     

     

     

     

    Descovy – U.S.

     

     

    563

     

     

    457

     

     

    1,902

     

     

    1,771

    Descovy – Europe

     

     

    25

     

     

    25

     

     

    100

     

     

    100

    Descovy – Rest of World

     

     

    28

     

     

    28

     

     

    110

     

     

    114

     

     

     

    616

     

     

    509

     

     

    2,113

     

     

    1,985

     

     

     

     

     

     

     

     

     

    Genvoya – U.S.

     

     

    410

     

     

    447

     

     

    1,498

     

     

    1,752

    Genvoya – Europe

     

     

    42

     

     

    48

     

     

    180

     

     

    205

    Genvoya – Rest of World

     

     

    18

     

     

    22

     

     

    84

     

     

    103

     

     

     

    470

     

     

    517

     

     

    1,762

     

     

    2,060

     

     

     

     

     

     

     

     

     

    Odefsey – U.S.

     

     

    252

     

     

    258

     

     

    957

     

     

    1,012

    Odefsey – Europe

     

     

    74

     

     

    71

     

     

    290

     

     

    294

    Odefsey – Rest of World

     

     

    11

     

     

    11

     

     

    41

     

     

    44

     

     

     

    336

     

     

    340

     

     

    1,288

     

     

    1,350

     

     

     

     

     

     

     

     

     

    Symtuza - Revenue share(1) – U.S.

     

     

    112

     

     

    104

     

     

    450

     

     

    382

    Symtuza - Revenue share(1) – Europe

     

     

    30

     

     

    32

     

     

    130

     

     

    133

    Symtuza - Revenue share(1) – Rest of World

     

     

    3

     

     

    3

     

     

    12

     

     

    13

     

     

     

    144

     

     

    139

     

     

    592

     

     

    529

     

     

     

     

     

     

     

     

     

    Other HIV(2) – U.S.

     

     

    67

     

     

    46

     

     

    257

     

     

    238

    Other HIV(2) – Europe

     

     

    33

     

     

    25

     

     

    129

     

     

    116

    Other HIV(2) – Rest of World

     

     

    11

     

     

    9

     

     

    48

     

     

    47

     

     

     

    111

     

     

    79

     

     

    434

     

     

    401

     

     

     

     

     

     

     

     

     

    Total HIV – U.S.

     

     

    4,532

     

     

    3,899

     

     

    15,918

     

     

    14,848

    Total HIV – Europe

     

     

    603

     

     

    533

     

     

    2,339

     

     

    2,102

    Total HIV – Rest of World

     

     

    317

     

     

    261

     

     

    1,355

     

     

    1,226

     

     

     

    5,452

     

     

    4,693

     

     

    19,612

     

     

    18,175

    Liver Disease

     

     

     

     

     

     

     

     

    Sofosbuvir / Velpatasvir(3) – U.S.

     

     

    185

     

     

    216

     

     

    922

     

     

    859

    Sofosbuvir / Velpatasvir(3) – Europe

     

     

    69

     

     

    74

     

     

    299

     

     

    323

    Sofosbuvir / Velpatasvir(3) – Rest of World

     

     

    75

     

     

    89

     

     

    374

     

     

    355

     

     

     

    330

     

     

    378

     

     

    1,596

     

     

    1,537

     

     

     

     

     

     

     

     

     

    Vemlidy – U.S.

     

     

    148

     

     

    115

     

     

    486

     

     

    410

    Vemlidy – Europe

     

     

    11

     

     

    10

     

     

    44

     

     

    38

    Vemlidy – Rest of World

     

     

    100

     

     

    92

     

     

    428

     

     

    414

     

     

     

    260

     

     

    217

     

     

    959

     

     

    862

     

     

     

     

     

     

     

     

     

    Other Liver Disease(4) – U.S.

     

     

    58

     

     

    39

     

     

    192

     

     

    152

    Other Liver Disease(4) – Europe

     

     

    54

     

     

    38

     

     

    202

     

     

    150

    Other Liver Disease(4) – Rest of World

     

     

    18

     

     

    19

     

     

    73

     

     

    83

     

     

     

    130

     

     

    96

     

     

    467

     

     

    385

     

     

     

     

     

     

     

     

     

    Total Liver Disease – U.S.

     

     

    391

     

     

    370

     

     

    1,601

     

     

    1,421

    Total Liver Disease – Europe

     

     

    134

     

     

    121

     

     

    545

     

     

    511

    Total Liver Disease – Rest of World

     

     

    194

     

     

    200

     

     

    876

     

     

    852

     

     

     

    719

     

     

    691

     

     

    3,021

     

     

    2,784

     

     

     

     

     

     

     

     

     

    Veklury

     

     

     

     

     

     

     

     

    Veklury – U.S.

     

     

    108

     

     

    364

     

     

    892

     

     

    972

    Veklury – Europe

     

     

    80

     

     

    181

     

     

    284

     

     

    408

    Veklury – Rest of World

     

     

    150

     

     

    175

     

     

    623

     

     

    805

     

     

     

    337

     

     

    720

     

     

    1,799

     

     

    2,184

     
     
     

    GILEAD SCIENCES, INC.

    PRODUCT SALES SUMMARY - (Continued)

    (unaudited)

     

     

     

    Three Months Ended

     

    Twelve Months Ended

     

     

    December 31,

     

    December 31,

    (in millions)

     

    2024

     

    2023

     

    2024

     

    2023

    Oncology

     

     

     

     

     

     

     

     

    Cell Therapy

     

     

     

     

     

     

     

     

    Tecartus – U.S.

     

     

    53

     

     

    66

     

     

    234

     

     

    245

    Tecartus – Europe

     

     

    36

     

     

    27

     

     

    138

     

     

    110

    Tecartus – Rest of World

     

     

    10

     

     

    5

     

     

    31

     

     

    15

     

     

     

    98

     

     

    98

     

     

    403

     

     

    370

     

     

     

     

     

     

     

     

     

    Yescarta – U.S.

     

     

    161

     

     

    187

     

     

    662

     

     

    811

    Yescarta – Europe

     

     

    156

     

     

    140

     

     

    666

     

     

    547

    Yescarta – Rest of World

     

     

    72

     

     

    42

     

     

    242

     

     

    140

     

     

     

    390

     

     

    368

     

     

    1,570

     

     

    1,498

     

     

     

     

     

     

     

     

     

    Total Cell Therapy – U.S.

     

     

    213

     

     

    253

     

     

    896

     

     

    1,055

    Total Cell Therapy – Europe

     

     

    193

     

     

    167

     

     

    804

     

     

    658

    Total Cell Therapy – Rest of World

     

     

    82

     

     

    46

     

     

    274

     

     

    156

     

     

     

    488

     

     

    466

     

     

    1,973

     

     

    1,869

     

     

     

     

     

     

     

     

     

    Trodelvy

     

     

     

     

     

     

     

     

    Trodelvy – U.S.

     

     

    247

     

     

    226

     

     

    902

     

     

    777

    Trodelvy – Europe

     

     

    77

     

     

    48

     

     

    294

     

     

    217

    Trodelvy – Rest of World

     

     

    31

     

     

    24

     

     

    119

     

     

    68

     

     

     

    355

     

     

    299

     

     

    1,315

     

     

    1,063

     

     

     

     

     

     

     

     

     

    Total Oncology – U.S.

     

     

    461

     

     

    479

     

     

    1,798

     

     

    1,833

    Total Oncology – Europe

     

     

    269

     

     

    216

     

     

    1,098

     

     

    875

    Total Oncology – Rest of World

     

     

    113

     

     

    70

     

     

    393

     

     

    224

     

     

     

    843

     

     

    765

     

     

    3,289

     

     

    2,932

    Other

     

     

     

     

     

     

     

     

    AmBisome – U.S.

     

     

    7

     

     

    4

     

     

    44

     

     

    43

    AmBisome – Europe

     

     

    66

     

     

    68

     

     

    276

     

     

    260

    AmBisome – Rest of World

     

     

    36

     

     

    39

     

     

    212

     

     

    189

     

     

     

    109

     

     

    111

     

     

    533

     

     

    492

     

     

     

     

     

     

     

     

     

    Other(5) – U.S.

     

     

    51

     

     

    64

     

     

    255

     

     

    261

    Other(5) – Europe

     

     

    8

     

     

    9

     

     

    34

     

     

    40

    Other(5) – Rest of World

     

     

    16

     

     

    17

     

     

    68

     

     

    66

     

     

     

    76

     

     

    90

     

     

    356

     

     

    367

     

     

     

     

     

     

     

     

     

    Total Other – U.S.

     

     

    59

     

     

    68

     

     

    299

     

     

    304

    Total Other – Europe

     

     

    74

     

     

    77

     

     

    310

     

     

    301

    Total Other – Rest of World

     

     

    52

     

     

    56

     

     

    280

     

     

    255

     

     

     

    184

     

     

    201

     

     

    889

     

     

    859

     

     

     

     

     

     

     

     

     

    Total product sales – U.S.

     

     

    5,550

     

     

    5,180

     

     

    20,508

     

     

    19,377

    Total product sales – Europe

     

     

    1,160

     

     

    1,128

     

     

    4,576

     

     

    4,197

    Total product sales – Rest of World

     

     

    826

     

     

    762

     

     

    3,526

     

     

    3,361

     

     

    $

    7,536

     

    $

    7,070

     

    $

    28,610

     

    $

    26,934

    ________________________________

    (1)

    Represents Gilead's revenue from cobicistat ("C"), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

    (2)

    Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada and Tybost.

    (3)

    Includes Epclusa and the authorized generic version of Epclusa sold by Gilead's separate subsidiary, Asegua Therapeutics LLC ("Asegua").

    (4)

    Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Livdelzi, Sovaldi, Viread and Vosevi.

    (5)

    Includes Cayston, Jyseleca, Letairis, Ranexa and Zydelig.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250211220195/en/

    Investors:

    Jacquie Ross, CFA

    [email protected]

    Media:

    Ashleigh Koss

    [email protected]

    Get the next $GILD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GILD

    DatePrice TargetRatingAnalyst
    4/22/2025$125.00Overweight
    Cantor Fitzgerald
    3/4/2025$115.00 → $132.00Outperform
    Oppenheimer
    2/18/2025$120.00Hold → Buy
    Deutsche Bank
    2/13/2025$108.00Hold → Buy
    DZ Bank
    1/10/2025$87.00 → $113.00Equal-Weight → Overweight
    Morgan Stanley
    12/10/2024$109.00Buy
    BofA Securities
    11/15/2024$110.00Outperform
    Wolfe Research
    11/14/2024$125.00Buy
    Citigroup
    More analyst ratings

    $GILD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald resumed coverage on Gilead Sciences with a new price target

      Cantor Fitzgerald resumed coverage of Gilead Sciences with a rating of Overweight and set a new price target of $125.00

      4/22/25 7:32:53 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer reiterated coverage on Gilead Sciences with a new price target

      Oppenheimer reiterated coverage of Gilead Sciences with a rating of Outperform and set a new price target of $132.00 from $115.00 previously

      3/4/25 8:15:52 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences upgraded by Deutsche Bank with a new price target

      Deutsche Bank upgraded Gilead Sciences from Hold to Buy and set a new price target of $120.00

      2/18/25 7:09:02 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GILD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Horning Sandra was granted 1,516 shares, increasing direct ownership by 42% to 5,147 units (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      5/8/25 8:26:11 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Manwani Harish covered exercise/tax liability with 296 shares and was granted 1,516 shares, increasing direct ownership by 9% to 14,093 units (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      5/8/25 8:18:19 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Kramer Kelly A.

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      5/8/25 8:17:07 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GILD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

      – 90% of Adults with Chronic Hepatitis Delta Virus (HDV) who Achieved Undetectable HDV RNA at 96 Weeks of Treatment with Bulevirtide Remained Undetectable for Almost 2 Years After Stopping Treatment – Gilead Sciences Inc. (NASDAQ:GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with chronic hepatitis delta virus (HDV) treated with the first-in-class entry inhibitor bulevirtide at either a 2 mg or 10 mg dose maintained virologic suppression for almost two years after stopping treatment after achieving undetectable HDV RNA at end of treatment (EOT). In participants who sustained undetectability for one year after end

      5/7/25 2:30:00 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025

      – 60% of Participants with Prior Fibrate or Obeticholic Acid Treatment Achieve Biochemical Response with Livdelzi – – New Evidence Supports Livdelzi Delivers Clinically and Statistically Significant Improvements in Pruritus – Gilead Sciences, Inc. (NASDAQ:GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated for the treatment of primary biliary cholangitis (PBC) and also provides sustained biochemical response in adults with PBC regardless of prior treatment history. Another analysis provides evidence supporting that Livdelzi delivered clinically and statistical

      5/7/25 2:15:00 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences to Present at Upcoming Investor Conferences

      Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Care Conference on Tuesday, May 13 at 11:20 AM Pacific Time RBC Capital Markets Global Healthcare Conference on Wednesday, May 21 at 11:30 AM Eastern Time Bernstein Annual Strategic Decisions Conference on Thursday, May 29 at 2:30 PM Eastern Time Jefferies Global Healthcare Conference on Wednesday, June 4 at 11:05 AM Eastern Time Goldman Sachs Annual Global Healthcare Conference on Tuesday, June 10 at 11:20 AM Eastern Time The live webcasts can be accessed at the company's investors page at investors.gilead.com. The replays wi

      4/29/25 4:05:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GILD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gilead Sciences, Inc. converted options into 3,216,119 shares and bought $20,020,000 worth of shares (910,000 units at $22.00) (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Reporting)

      2/13/24 5:48:49 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GILD
    Financials

    Live finance-specific insights

    See more
    • Gilead Sciences Announces First Quarter 2025 Financial Results

      Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.3 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.1 billion Gilead Sciences, Inc. (NASDAQ:GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "Our base business grew 4% year-over-year, primarily led by Biktarvy's continued strength, and we announced positive topline Phase 3 results for Trodelvy plus pembrolizumab in first line PD-L1+ metastatic triple negative breast cancer. With the upcoming June P

      4/24/25 4:02:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025

      Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2025 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The compa

      4/10/25 4:05:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend

      Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared an increase of 2.6% in the company's quarterly cash dividend, beginning in the first quarter of 2025. The increase will result in a quarterly dividend of $0.79 per share of common stock. The dividend is payable on March 28, 2025, to stockholders of record at the close of business on March 14, 2025. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is commi

      2/11/25 4:05:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GILD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

      11/26/24 4:36:21 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

      11/26/24 4:36:21 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

      11/15/24 4:36:27 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GILD
    SEC Filings

    See more
    • Gilead Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

      5/8/25 5:26:08 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Gilead Sciences Inc.

      10-Q - GILEAD SCIENCES, INC. (0000882095) (Filer)

      5/7/25 4:32:49 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

      4/24/25 4:03:59 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GILD
    Leadership Updates

    Live Leadership Updates

    See more
    • Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

      4/28/25 4:05:00 PM ET
      $CTNM
      $GILD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

      Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead's senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD. Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines across a broad range of therapeutic areas. He will assume responsibility for the Company's leading virology, oncology and inflammation portfolio and will oversee the company's global Development and Medical Affairs organizations. "Dietmar's exceptional leadership in

      12/12/24 5:30:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer

      Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Thad Huston as Chief Financial Officer (CFO) and Chief Operating Officer (COO) as per 1 July 2023. Mr. Huston will be a member of the Executive Committee of Galapagos and will join Galapagos from Kite, a Gilead Company (NASDAQ:GILD). He brings 30 years of global finance and operational experience in healthcare with an excellent track record of driving business transformation and innovation. "On behalf of the Board of Directors and management of Galapagos, I extend a warm welcome to Thad. Thad is a widely recognized leader with a strong internationa

      6/15/23 4:01:00 PM ET
      $GILD
      $GLPG
      $JNJ
      $LIVN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $GILD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

      SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

      2/9/24 6:21:28 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

      SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

      2/13/23 3:32:27 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Gilead Sciences Inc.

      SC 13G - GILEAD SCIENCES, INC. (0000882095) (Subject)

      2/13/23 2:49:26 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care